MedTrace Logo

An Initial Evaluation of AN8025 in Solid Tumors

NCT07639047 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2026-06-10

No results posted yet for this study

Summary

The goal of this clinical trial is to determine the appropriate dose of AN8025 for use in the treatment of advanced solid tumors. This study will be conducted in in adults \>18 years of age. The main questions to answer:

1. Determine which dose level of AN8025 is safe and tolerability in participants with advanced solid tumors
2. To determine the maximum tolerated of AN8025 for future testing.

Participants will visit their study site in 3 week cycles, during which they will be under go treatment with AN8025 and visit their clinical site during each cycle for check ups and testing.

Conditions

  • Advanced Solid Tumor (Phase 1)

Interventions

DRUG

AN8025 is a multifunctional antibody fusion protein

AN8025 is being developed for the treatment of advanced or metastatic solid tumors, which may include PD(L)-1 refractory advanced solid tumors

Sponsors & Collaborators

  • Adlai Nortye Biopharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2027-07-31
Completion
2028-01-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07639047 on ClinicalTrials.gov